Cindy Boer

Vitamin K Antagonist Anticoagulants and Osteoarthritis | 141 3.2 ▲ Figure 1: Acenocoumarol use interacts with MGP OA risk single nucleoti de variants (SNVs) and VKORC1 haplotype groups, leading to increased risk of overall progression of osteoarthriti s. VKORC1 haplotype groups are based on the VKORC1 H-haplotypes, which can be divided into three groups based on their VKA dosage/VKORC1 expression associati on: AA = low VKA dose/VKORC1 expression, AB=intermediate VKA dose/VKORC1 expression and BB = high VKA dose/VKORC1 expression. c) Aceno- coumarol use in VKORC1 BB haplotype carriers and MGP risk allele carriers and OA risk. OR, CI and p- value based on GEE multi variate logisti c regression adjusted for age, sex, BMI, smoking, ti me between baseline and follow-up visit, baseline OA severity in Kellgren-Lawrence score, joint modeled, femoral neck BMD, HDL/total cholesterol rati o, physical acti vity, educati on level, hypertension and diabetes mel-lites. OA: osteoarthriti s, A/A: non carrier of MGP risk allele, T/*: carrier of MGP risk allele. VKORC1 AA: homozygous VKORC1 A haplotype carriers, VKORC1 BB: homozygous VKORC1 BB haplotype carriers OR: odds rati o, error bars indicate 95% Confi dence Interval (CI) for the OR. P-values belong to depicted OR. See Supplementary Table 3 for the exact values depicted in this graph. altered VKORC1 expression had an altered risk for overall incidence and progression of OA. The study population was stratified in MGP risk allele carriers (T/*) and non-carri- ers (A/A)( Table 1 ). Within acenocoumarol users among both MGP genotype groups had a sig- nificantly higher risk of overall OA progression than non-users ( Table 3 ). Using the VKORC1 -Haplotypes, the study population could be also stratified into low (AA), inter- mediate (AB), and high (BB) VKORC1 expression/VKA dose groups[23]( Table 1 and Supplementary Table S1 ). Similarly to the MGP genotypes, we observed no effect of the VCORC1 genotypes on the risk for overall OA incidence/progression ( Table 3 ), al- though the VKORC1 -BB group had the highest risk of overall OA progression (OR=3.35, 95% CI=2.22-5.05, Table 3 ).